Proposed cancellation
Company proposes to cancel AIM listing and re-register as private limited company.
Select text to share a quote on X · sign in to keep highlights & notes in your AGY notes
Adoption of New Articles of Association
and
Notice of Annual General Meeting
Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, today announces the proposed cancellation of the admission of its ordinary shares to trading on AIM (the "Cancellation"), re-registration of the Company as a private limited company (the "Re-registration") and the adoption of new articles of association (the "New Articles").
Following publication of the Annual Report and Accounts for the year ended 30 June 2026 (the "2026 Accounts") a Notice of Annual General Meeting ("Notice") will today be sent to Shareholders, setting out the background to and reasons for the proposed Cancellation and the Re-registration and associated adoption of the New Articles. The Notice will also contain a notice convening the Company’s Annual General Meeting ("AGM"), at which Shareholders are invited to consider and, if thought fit, approve Resolutions 11 and 12, concerning the proposed Cancellation and the Re-Registration and the associated adoption of the New Articles.
The AGM will be held at the offices of DLA Piper UK LLP, 160 Aldersgate Street, London, EC1A 4HT on 14 December 2026 at 10.00 a.m.
The Directors consider that the proposals are in the best interests of the Company and its shareholders as a whole and, therefore, unanimously recommend that you vote in favour of the proposals at the AGM as each of the Directors intends to vote, or procure the vote, in respect of, in aggregate, 9,167,707 Ordinary Shares to which they are beneficially entitled, representing approximately 0.14% of the Company's issued ordinary share capital.
The Board has received oral commitments from the Company’s two largest shareholders, SkyGem and Southern Fox, who together hold 87.98% of the issued shares, that they are supportive of the Cancellation and Re-registration and intend to vote in favour of the Cancellation Resolution and Re-registration Resolution.
The Notice will be made available shortly on the Company's website at www.allergytherapeutics.com and capitalised terms used in this announcement, unless otherwise defined, shall have the meaning ascribed to them in the Notice.
Process for Cancellation
Under the AIM Rules, it is a requirement that the Cancellation must be approved by Shareholders holding not less than 75 per cent. of votes cast by Shareholders at the AGM. Accordingly, the Notice contains a special resolution to approve the Cancellation (the “Cancellation Resolution).
In accordance with AIM Rule 41, the Directors have notified the London Stock Exchange of the Company's intention, subject to the Cancellation Resolution being passed at the AGM on 14 December 2026, to cancel the Company's admission of the Ordinary Shares to trading on AIM. Accordingly, if the Cancellation Resolution is passed by the Shareholders, the Cancellation will become effective at 7.00 a.m. on 22 December 2026.
The full timetable of expected events is set out at the end of this announcement.
Process for Re-registration
Following the Cancellation, the Directors believe that the requirements and associated costs of the Company maintaining its public company status will be difficult to justify and that the Company will benefit from the more flexible requirements and lower costs associated with private limited company status. It is therefore proposed to re-register the Company as a private limited company. In connection with the Re-registration, it is proposed that the New Articles be adopted to reflect the change in the Company's status to a private limited company. The principal effects of the Re-registration and the adoption of the New Articles on the rights and obligations of Shareholders and the Company will be summarised in the Notice. Under the Companies Act 2006, the Re-registration and the adoption of the New Articles must be approved by Shareholders holding not less than 75 per cent. of votes cast by Shareholders at the AGM (the "Re-registration Resolution").
If the Cancellation Resolution and the Re-registration Resolution are approved at the AGM, an application will be made to the Registrar of Companies for the Company to be re-registered as a private limited company. Re-registration will take effect when the Registrar of Companies issues a certificate of incorporation on Re-registration. The Registrar of Companies will issue the certificate of incorporation on Re-registration when it is satisfied that no valid application can be made to cancel the Re-registration Resolution or that any such application to cancel the Re-registration Resolution has been determined and confirmed by the Court.
Directorate Changes
Conditional upon, and with effect from, the Cancellation, each of Cheryl MacDiarmid, Tunde Otulana, David Ball and Lawrence Allen Wang (being all of the independent Non-Executive Directors) will step down as Directors of the Company. The Board would like to thank them for their contribution to the Company. Following the Cancellation, the Board will comprise Helge Weiner-Trapness (as executive chair), Manuel Llobet (as CEO) and Dr Shaun Furlong (as CFO). Anthony Parker and Zheqing (Simon) Shen will also retain their director roles as shareholder representatives of each of Southern Fox and SkyGem (respectively). The Company will no longer maintain a separate audit committee, remuneration committee or nomination committee, the functions of which will be carried out by the Board as a whole.
Trading in the Ordinary Shares before and after Cancellation
The Board is aware that, following the Cancellation, Shareholders may still wish to buy or sell Ordinary Shares. The Company has therefore arranged for a matched bargain trading facility (the “Matched Bargain Facility”) to be provided by JP Jenkins from the date of the Cancellation, subject to the Cancellation Resolution being passed. JP Jenkins is a company incorporated in England & Wales with registered number 08014724 and whose registered office is at 101 Wigmore Street, 5th Floor, London, England, W1U 1QU. JP Jenkins (FRN 1037394, PAN 25002) is authorised and regulated by the Financial Conduct Authority.
Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with JP Jenkins, through their stockbroker (JP Jenkins is unable to deal directly with members of the public), of the number of Ordinary Shares they are prepared to buy or sell at an agreed price. If JP Jenkins is able to match that order with an opposite buy or sell instruction, it will contact both parties and then effect the trade. Shareholdings will remain in CREST and can be traded during normal business hours through a UK regulated stockbroker. Shareholders who hold their Ordinary Shares in certificated form and wish to use the Matched Bargain Facility may first need to deposit their Ordinary Shares into CREST through their stockbroker.
Details of the Matched Bargain Facility will be made available to Shareholders on the Company’s website at www.allergytherapeutics.com and directly by letter or email (where appropriate). The indicative price and transaction history of the Ordinary Shares will be available on the JP Jenkins website at www.jpjenkins.com. A trading fee of 1.5% (subject to a minimum charge of £25) is payable on each trade, and additional fees may be charged by Shareholders’ own stockbrokers. Stamp duty or stamp duty reserve tax may be payable on purchases of Ordinary Shares.
The Matched Bargain Facility will operate for a minimum of 12 months following the Cancellation. The Directors’ current intention is that it will continue beyond that time. However, there can be no guarantee that the Matched Bargain Facility will continue to operate after that period, and if it is withdrawn Shareholders’ ability to trade Ordinary Shares will be further restricted. Shareholders should also note that there can be no guarantee as to the level of liquidity or marketability of the Ordinary Shares under the Matched Bargain Facility, or that Shareholders will be able to realise their investment through it. Further details will be communicated to Shareholders at the relevant time.
| Latest time for receipt of proxy appointments in respect of the Annual General Meeting | 10:00 a.m. on 10 December 2026 |
| Annual General Meeting | 10:00 a.m. on 14 December 2026 |
| Announcement of result of Annual General Meeting | 14 December 2026 |
| Expected Last day of dealings in Ordinary Shares on AIM | 21 December 2026 |
| Expected time and date of Cancellation | 7:00 a.m. on 22 December 2026 |
| Expected re-registration as a private company | Week commencing 11 January 2027 |
Notes:
- Unless otherwise specified, references in this document to time are to the relevant time in the United Kingdom.
- The times and dates above are indicative only. If there is any change, revised times and dates will be notified to Shareholders by means of an announcement through a Regulatory Information Service.
Background to and reasons for the Proposed Cancellation and Re-registration
Following the refinancings undertaken by the Group over the last 18 months with its three largest shareholders, SkyGem Acquisitions Limited ("SkyGem"), Southern Fox Investments ("Southern Fox") and Hayfin Healthcare Opportunities LuxCo S.a.r.l, ("Hayfin"), only around 9% of the current Ordinary Shares in issue are held in public hands. Despite the Company's positive commercial and operational progress, the Board feels this lack of free float, together with wider challenges around market liquidity, is negatively impacting the Company's share price. This, together with the challenging financial conditions in recent years, has caused the Board to consider, over a period of time, the benefits and drawbacks to the Company and its Shareholders of retaining the admission of the Ordinary Shares to trading on AIM. Following that review, the Board has concluded, having regard to the Group’s strategy and its near and medium-term growth plans, that the Cancellation is in the best interests of the Company and its Shareholders as a whole. In reaching this conclusion, the Board has considered the following key factors:
- Costs and regulatory burden: the considerable ongoing cost of maintaining the admission of the Ordinary Shares to trading on AIM, which is in excess of £1 million per annum (including nominated adviser and broker fees, London Stock Exchange fees, and the legal, audit, registrar, financial public relations and other costs associated with being a listed company including non-executive director fees), is, in the Board’s opinion, disproportionate to the benefits to the Company. The Directors believe that these funds could be better used to support the Group’s working capital and growth plans;
- Management time: a significant proportion of management time is spent on the legal and regulatory requirements associated with maintaining the admission of the Ordinary Shares to trading on AIM. This is, in the Directors’ opinion, disproportionate to the benefits to the Company, and that time could be more effectively applied to the operation and development of the Group’s business;
- Access to capital: the Directors believe that raising further significant equity capital through AIM could be challenging in the short or medium term and potentially may not be available at a valuation that is acceptable to shareholders, or at all. The Board believes that, as a private company, the Group will be better placed to access funding on improved terms;
- Valuation: despite the Company's positive commercial and operational progress, the Directors believe that the Company’s share price does not currently reflect the underlying value or prospects of the Group. Further, as an unlisted company the Board can better take and implement strategic decisions that will assist the business in creating long term value, whilst as a listed company the Board believes such strategic decisions could be viewed negatively as they may affect short-term financial performance which is likely to negatively affect investor sentiment and therefore the share price and reputation of the Company;
- Limited liquidity and free float: trading in the Ordinary Shares is limited, with an average daily trading volume over the 12 months to 16 November 2026 of approximately 444,544 Ordinary Shares, representing approximately 0.01% of the Company’s issued share capital. Approximately 91.14% of the Ordinary Shares are held by the Directors, employees and strategic holders. The Directors do not believe that the current level of liquidity offers investors the opportunity to trade in meaningful volumes or with frequency; and
- Quicker strategic decisions: an unlisted company can take and implement strategic decisions faster than a company which is publicly traded because of the more flexible regulatory regime that is applicable to an unlisted company. This will be advantageous in the Company’s strategy which may ultimately benefit the Company and Shareholders as a whole.
Following careful consideration of the above factors and the long-term interests of the business, the Board believes that it is in the best interests of the Company and its Shareholders as a whole to seek the Cancellation at the earliest opportunity in accordance with Rule 41 of the AIM Rules, and thereafter to re-register the Company as a private limited company.
The Board acknowledges that certain Shareholders may be unable or unwilling to hold shares in a company whose shares are not admitted to trading on AIM or any other public market. The Board has therefore considered how best to provide liquidity for those Shareholders and intends to put in place the Matched Bargain Facility described above.
Annual General Meeting
The Company is convening the AGM to consider and, if thought fit, pass: (i) a special resolution to approve the Cancellation, and (ii) a special resolution to approve the Re-registration (including approving the New Articles).
The AGM will be held at the offices of DLA Piper UK LLP, 160 Aldersgate Street, London, EC1A 4HT on 14 December 2026 at 10.00 a.m.
Shareholders are requested to register their proxy votes no later than 10.00 a.m. on 10 December 2026 online via the Investor Centre app or at https://uk.investorcentre.mpms.mufg.com/. Shareholders may also request a paper proxy form from the Company’s registrar, MUFG Corporate Markets by calling 0371 664 0300 (if calling from the United Kingdom), or +44 371 664 0300 (if calling from outside of the United Kingdom), or emailing shareholderenquiries@cm.mpms.mufg.com.
Shareholders who are CREST members may submit their CREST Proxy Instructions online via the CREST electronic appointment service. Further details of how to register your proxy vote are contained within the notes to the Notice of AGM. The return of a form of proxy will not preclude a shareholder from attending and voting at the AGM if he/she so wishes. You are urged to appoint the chair of the AGM as your proxy, with voting instructions, in advance of the AGM.
Persons intending to attend the AGM in person will need to pre-register their intention to do so by emailing cosec@allergytherapeutics.com (please state ‘Allergy Therapeutics plc: AGM’ in the subject line of the email and include your full name and investor code, which can be found on your share certificate or, by contacting the Registrar, MUFG Corporate Markets (contact details above) by no later than 10.00 a.m. on 10 December 2026).
A copy of the Notice containing full details and instructions for the AGM and the New Articles will be made available on the Company's website at www.allergytherapeutics.com.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.